| Content Provider |
World Health Organization (WHO)-Global Index Medicus |
| Author |
Li, Pei Zhang, Ruijie Gan, Yibo Wang, Liyuan Zhao, Chen Luo, Lei Zhang, Chengmin Zhou, Qiang |
| Description |
Country affiliation: China Author Affiliation: Li P ( Department of Orthopedic Surgery, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.); Zhang R ( Department of Respiratory Medicine, the Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.); Gan Y ( Department of Orthopedic Surgery, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.); Wang L ( Department of Orthopedic Surgery, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.); Zhao C ( Department of Orthopedic Surgery, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.); Luo L ( Department of Orthopedic Surgery, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.); Zhang C ( Department of Orthopedic Surgery, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.); Zhou Q ( Department of Orthopedic Surgery, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China. Electronic address: zq_tlh@163.com.) |
| Abstract |
Osteogenic protein (OP)-1 delivery into discs has achieved some success in disc regeneration in animals, though conflicting outcomes exist. This study aimed to systematically review the animal studies that assessed the effect of OP-1 on disc regeneration. Relevant literature was searched in the following databases: PubMed, MEDLINE, EMBASE, the Cochrane Library, China National Knowledge Internet (CNKI) and Chinese BioMedical Literature Database (CBM). Animal species, disc degeneration model, OP-1 delivery method, and follow-up methodology including disc histology, disc matrix alteration, disc height, MRI T2 signal intensity and OP-1 treatment complications were extracted and reviewed. Among 15 eligible studies, direct OP-1 protein injection into the disc was reported in 10 studies whereas cell-based or viral-based OP-1 gene transfer into the disc was reported in 5 studies. Although one study using a spontaneous canine disc degeneration model reported negative findings, all other studies (10 in rabbit, 1 in canine and 3 in rat) indicated that OP-1 delivery was effective in retarding disc degeneration and regenerating discs. The adverse effect of OP-1 delivery (i.e., extradiscal new bone formation) was reported in one study. In conclusion, OP-1 delivery offers a feasible option to biologically treat degenerated discs in animals, especially in rodent rabbit and rat models. However, more animal studies are needed to test the safety of the current OP-1 delivery means. Additionally, care should be taken when OP-1 delivery is used to treat human disc degeneration due to the differences between human and animal discs. |
| File Format |
HTM / HTML |
| ISSN |
07533322 |
| Volume Number |
88 |
| e-ISSN |
19506007 |
| Journal |
Biomedicine & Pharmacotherapy |
| Language |
English |
| Publisher |
Elsevier |
| Publisher Date |
2017-04-01 |
| Publisher Place |
France |
| Access Restriction |
One Nation One Subscription (ONOS) |
| Subject Keyword |
Discipline Pharmacology Bone Morphogenetic Protein 7 Pharmacology Therapeutic Use Intervertebral Disc Degeneration Drug Therapy Regeneration Drug Effects Animals Humans Intervertebral Disc Journal Article Review |
| Content Type |
Text |
| Resource Type |
Article |
| Subject |
Medicine Pharmacology |
